Calidi Biotherapeutics Inc [CLDI] stock prices are up 29.43% to $0.21 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CLDI shares have gain 33.33% over the last week, with a monthly amount drifted -63.19%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Calidi Biotherapeutics Inc [AMEX: CLDI] stock has seen the most recent analyst activity on November 22, 2023, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $11. Previously, Robert W. Baird started tracking the stock with Outperform rating on October 09, 2023, and set its price target to $9.
The stock price of Calidi Biotherapeutics Inc [CLDI] has been fluctuating between $0.14 and $13.79 over the past year. Currently, Wall Street analysts expect the stock to reach $5.5 within the next 12 months. Calidi Biotherapeutics Inc [AMEX: CLDI] shares were valued at $0.21 at the most recent close of the market. An investor can expect a potential return of 2519.05% based on the average CLDI price forecast.
Analyzing the CLDI fundamentals
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.1386 points at the first support level, and at 0.0691 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.2988, and for the 2nd resistance point, it is at 0.3895.
Calidi Biotherapeutics Inc [CLDI] reported earnings per share of -$0.48 for its fiscal quarter that ended on 12/31/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.2/share, meaning a difference of -$0.28 and a surprise factor of -140.00%. By comparison, the stated earnings for the previous quarter ended on 9/30/2023 were -$0.14 per share as compared to estimates of -$0.17 per share, a difference of $0.03 representing a surprise of 17.60%.
Ratios To Look Out For
It’s worth pointing out that Calidi Biotherapeutics Inc [AMEX:CLDI]’s Current Ratio is 0.42. Further, the Quick Ratio stands at 0.42.
